PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25964201-7	2015	Interestingly, cross-resistance to imatinib and enzastaurin (selective inhibitors of c-Kit and PKC-beta, respectively), was observed and the use of YK-4-279 with enzastaurin in vitro led to marked drug synergy, suggesting a potential role for combination therapies in the future.	Imatinib Mesylate	35-43	protein kinase C beta	Homo sapiens	95-103